JP2018516937A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516937A5
JP2018516937A5 JP2017562994A JP2017562994A JP2018516937A5 JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5 JP 2017562994 A JP2017562994 A JP 2017562994A JP 2017562994 A JP2017562994 A JP 2017562994A JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5
Authority
JP
Japan
Prior art keywords
pain
composition
item
eudragit
constipation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/035886 external-priority patent/WO2016197042A1/en
Publication of JP2018516937A publication Critical patent/JP2018516937A/ja
Publication of JP2018516937A5 publication Critical patent/JP2018516937A5/ja
Pending legal-status Critical Current

Links

JP2017562994A 2015-06-05 2016-06-03 リナクロチドの改変または標的放出製剤 Pending JP2018516937A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171462P 2015-06-05 2015-06-05
US62/171,462 2015-06-05
US201662339462P 2016-05-20 2016-05-20
US62/339,462 2016-05-20
PCT/US2016/035886 WO2016197042A1 (en) 2015-06-05 2016-06-03 Modified or targeted release formulations of linaclotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020166911A Division JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤

Publications (2)

Publication Number Publication Date
JP2018516937A JP2018516937A (ja) 2018-06-28
JP2018516937A5 true JP2018516937A5 (https=) 2019-07-04

Family

ID=56133109

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017562994A Pending JP2018516937A (ja) 2015-06-05 2016-06-03 リナクロチドの改変または標的放出製剤
JP2020166911A Withdrawn JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤
JP2022164508A Withdrawn JP2022179727A (ja) 2015-06-05 2022-10-13 リナクロチドの改変または標的放出製剤
JP2024140831A Pending JP2024161048A (ja) 2015-06-05 2024-08-22 リナクロチドの改変または標的放出製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020166911A Withdrawn JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤
JP2022164508A Withdrawn JP2022179727A (ja) 2015-06-05 2022-10-13 リナクロチドの改変または標的放出製剤
JP2024140831A Pending JP2024161048A (ja) 2015-06-05 2024-08-22 リナクロチドの改変または標的放出製剤

Country Status (5)

Country Link
US (2) US20190350863A1 (https=)
EP (1) EP3302440B1 (https=)
JP (4) JP2018516937A (https=)
ES (1) ES2868873T3 (https=)
WO (1) WO2016197042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007574A (es) * 2016-12-21 2019-09-04 Ironwood Pharmaceuticals Inc Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida.
WO2020251923A1 (en) * 2019-06-10 2020-12-17 Ironwood Pharmaceuticals, Inc. Treatment of abdominal pain associated with diarrhea-predominant irritable bowel syndrome
CN116056719A (zh) * 2020-06-30 2023-05-02 索伦·欧克维克 包含鸟苷酸环化酶c(gucy2c)激动剂和短链脂肪酸或其前药的组合的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110543A1 (es) * 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
US20100221329A1 (en) * 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
EP2603232B1 (en) * 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням

Similar Documents

Publication Publication Date Title
KR101799625B1 (ko) 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
KR101799624B1 (ko) 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
El-Zahaby et al. Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate
CA2984434C (en) Monolithic tablets based on carboxyl polymeric complexes for controlled drug release
KR101767288B1 (ko) 복용 용이성 고형 제제
JP2017504590A5 (https=)
JP2013522373A (ja) 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
HRP20231699T1 (hr) Formulacije inhibitora amorfne kinaze i postupci njihove primjene
JP2023509629A5 (https=)
JP6768070B2 (ja) 粘膜付着性医薬組成物及びその製造方法
CN103269691A (zh) 用于控制释放美沙拉嗪的口服药物片剂和其获得方法
CN105025888B (zh) 肠溶片
WO2017022248A1 (ja) 腸溶性カプセル
JP2018516937A5 (https=)
Ramli et al. Coatless alginate pellets as sustained-release drug carrier for inflammatory bowel disease treatment
Segale et al. Calcium alginate multi-unit oral dosage form for delayed release of celecoxib
CN110475557B (zh) 固体分散体
Newton et al. Effect of HPMC-E15 LV premium polymer on release profile and compression characteristics of chitosan/pectin colon targeted mesalamine matrix tablets and in vitro study on effect of pH impact on the drug release profile
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
CN118234489A (zh) 吡啶酮衍生物的口服制剂及其在肠纤维化的预防和/或治疗中的用途
Tiwari et al. Enhancement of site specific delivery of diloxanide furoate as an antiamoebic drug
CA3060026A1 (en) Polymer based formulation for release of drugs and bioactives at specific git sites
Elghamry et al. Formulation and evaluation of colon targeted pulsincap delivery of Carvedilol for treatment of hypertension
Raffin et al. Pantoprazole sodium-loaded controlled release microparticles prepared by spray drying
Kopanar et al. COLON DRUG DELIVERY OF BERBERIN HYDROCHLORIDE